Cargando…

PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

In recent years, the deoxycytidine analogue gemcitabine (2′,2′,-difluorodeoxycytidine) has become the first-line chemotherapeutic agent for patients with pancreatic cancer. However, due to the intrinsic resistance of pancreatic cancer cells, gemcitabine-based chemotherapy yields limited disease cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wenbin, Zhu, Yue, Zhang, Kelin, Yu, Xianhuan, Lin, Haoming, Wu, Wenrui, Peng, Yaorong, Sun, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156657/ https://www.ncbi.nlm.nih.gov/pubmed/32123287 http://dx.doi.org/10.1038/s12276-020-0390-4

Ejemplares similares

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway
por: Zhang, Zhiqi, et al.
Publicado: (2022)

Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells
por: Amrutkar, Manoj, et al.
Publicado: (2019)

Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells
por: Khanna, Amit, et al.
Publicado: (2010)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer
por: Amrutkar, Manoj, et al.
Publicado: (2021)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2022)

Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway
por: Wei, Wei-Tian, et al.
Publicado: (2011)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Identification of chemoresistance‐related mRNAs based on gemcitabine‐resistant pancreatic cancer cell lines
por: Zhou, Jiarong, et al.
Publicado: (2019)

M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
por: Zhao, Yongmei, et al.
Publicado: (2021)

Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance
por: Saiki, Yuriko, et al.
Publicado: (2020)

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway
por: Namba, T, et al.
Publicado: (2015)

Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
por: Huanwen, Wu, et al.
Publicado: (2009)

Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion
por: SUMIYOSHI, HIROKI, et al.
Publicado: (2016)

Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma
por: Zhou, Liangjing, et al.
Publicado: (2019)

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Heme oxygenase‐1 induction mediates chemoresistance of breast cancer cells to pharmorubicin by promoting autophagy via PI3K/Akt pathway
por: Pei, Lei, et al.
Publicado: (2018)

DDK Promotes Tumor Chemoresistance and Survival via Multiple Pathways
por: Sasi, Nanda Kumar, et al.
Publicado: (2017)

HPRT1 Promotes Chemoresistance in Oral Squamous Cell Carcinoma via Activating MMP1/PI3K/Akt Signaling Pathway
por: Wu, Tong, et al.
Publicado: (2022)

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
por: Dhayat, Sameer A., et al.
Publicado: (2015)

Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer
por: Xun, Jingyu, et al.
Publicado: (2023)

GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway
por: Chang, Zhenyu, et al.
Publicado: (2019)

Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-κB Signaling Pathway in Human Pancreatic Ductal Adenocarcinoma
por: Chen, Dong, et al.
Publicado: (2012)

Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
por: Patel, Girijesh Kumar, et al.
Publicado: (2017)

Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway
por: Wu, Qiong, et al.
Publicado: (2013)

Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
por: Luo, Wenhao, et al.
Publicado: (2019)

Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer
por: Wei, Lusheng, et al.
Publicado: (2018)

ITGA2 Overexpression Promotes Esophageal Squamous Cell Carcinoma Aggression via FAK/AKT Signaling Pathway
por: Huang, Wei, et al.
Publicado: (2021)

TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer
por: Hara, Kazushi, et al.
Publicado: (2022)

PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway
por: Liu, Qian, et al.
Publicado: (2019)

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
por: Massihnia, Daniela, et al.
Publicado: (2017)

Patient‐reported outcome measures ( PROMs): making sense of individual PROM scores and changes in PROM scores over time
por: van der Willik, Esmee M., et al.
Publicado: (2020)

A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma
por: Pan, Ruogu, et al.
Publicado: (2021)

WAVE3 promotes proliferation, migration and invasion via the AKT pathway in pancreatic cancer
por: Huang, Shaobin, et al.
Publicado: (2018)

FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer
por: Hou, Junmei, et al.
Publicado: (2012)

Chemoresistance in Pancreatic Cancer
por: Zeng, Siyuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tclb71scvegus5hcjdfnn89s04